Kingsuk Ganguly, MD
Anesthesiology · Voorhees
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Chc Pain Management Center, PA · 12 clinicians in this group
Hospitals listed: Cooper University Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ganguly’s office at (856) 325-6505 to ask if they take your plan before you enroll.
California Medical Board record
Licence A118273 · Current
Licensed to practise in California · since 2011 · expires 2027-09-30 · Umdnj New Jersey Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- New Jersey 25MA09636600Medical Doctor · since 2015 · expires 2027-06-30ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Cooper University HospitalCamden, NJAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Cooper University Health CarePatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.4 (1.19 to 1.6), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.75 (2.56 to 4.93) · 1,636 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.66 (1.23 to 2.09) · 9,323 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.2 (11.1 to 15.3) · 711 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 16 (13.1 to 19.5) · 3,523 cases, Jan 2022 – Dec 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.493, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.758, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 0.9) · 1,210 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Cooper University Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.4 (1.19 to 1.6) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.75 (2.56 to 4.93) · 1,636 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.66 (1.23 to 2.09) · 9,323 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.2 (11.1 to 15.3) · 711 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 16 (13.1 to 19.5) · 3,523 cases | Worse | Jan 2022 – Dec 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.493 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.758 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 0.9) · 1,210 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.08 (0.32 to 1.84) · 2,500 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 202.38 (168.39 to 236.37) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 294 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.4 · 76 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 180 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 386 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 304 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 422 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 4,631 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 10,660 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.09 to 0.44) · 11,298 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.91 (2.45 to 5.36) · 4,011 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.69 (1.56 to 3.81) · 3,697 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.62 (3.59 to 11.65) · 1,520 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (3.65 to 8.52) · 1,640 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.99 (0.7 to 3.28) · 740 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.2 · 49 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.91 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.928 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.804 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.644 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 444 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 831 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.8 · 337 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.7 · 504 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.2 · 324 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.9 · 499 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (4.1 to 6.7) · 711 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.1 · 48 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 307 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 177 cases | None | Jul 2023 – Jun 2025 |
What patients said (2,158 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$79,426
Medicare paid this office $79,426 for 342 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 108 | $16,367 | $122 |
| New patient visit (45+ min) | 113 | $15,015 | $133 |
| Return visit (30+ min) | 84 | $9,331 | $98 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 73 | $4,816 | $53 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 36 | $4,542 | $116 |
See all 13 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 108 | $16,367 | $122 |
| New patient visit (45+ min) | 113 | $15,015 | $133 |
| Return visit (30+ min) | 84 | $9,331 | $98 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 73 | $4,816 | $53 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 36 | $4,542 | $116 |
| Injection of substance into middle or upper spine canal using imaging guidance | 37 | $3,807 | $85 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 27 | $3,631 | $107 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 19 | $2,173 | $91 |
| Injection of substance into lower spine canal using imaging guidance | 25 | $2,097 | $78 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 22 | $1,734 | $60 |
| Injection of substance into middle or upper spine canal using imaging guidance | 15 | $1,156 | $77 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 23 | $1,126 | $49 |
| Fluoroscopic guidance for needle placement | 14 | $352 | $22 |
Who their Medicare patients are
342 Original Medicare patients in 2024. Average age 70 · Under 65 22% · 85 and older 9% · Women 63% · Also on Medicaid 29% · Health risk score 1.47. At or below the middle of the specialty; the typical anesthesiology clinician is at 1.54.
Conditions among them: High blood pressure 75% · Diabetes 35% · Depression 33% · Coronary heart disease 25% · COPD 21% · Cancer 20% · Chronic kidney disease 19% · Heart failure 12% · Atrial fibrillation 12% · Stroke 9% · Dementia 6%.
The office billed $811,391, Medicare allowed $103,535 and paid $79,426; for 841 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 342 | 841 | 70 | 1.47 | $811,391 | $79,426 |
| 2023 | 272 | 738 | 68 | 1.52 | $714,307 | $70,341 |
| 2022 | 247 | 657 | 68 | 1.42 | $572,002 | $64,153 |
| 2021 | 255 | 664 | 66 | 1.87 | $410,972 | $63,923 |
| 2020 | 221 | 558 | 65 | 2.03 | $318,415 | $50,450 |
| 2019 | 293 | 647 | 64 | 1.93 | $352,394 | $58,540 |
| 2018 | 363 | 821 | 65 | 1.88 | $367,045 | $69,355 |
| 2017 | 409 | 879 | 64 | 1.96 | $323,126 | $78,353 |
| 2016 | 450 | 1,009 | 64 | 1.95 | $414,253 | $89,785 |
| 2015 | 245 | 461 | 64 | 1.48 | $148,635 | $41,063 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| New patient visit (45+ min) | 104 | $14,283 | $137 |
| Return visit (30+ min) | 82 | $10,857 | $94 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 68 | $10,840 | $120 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 63 | $9,453 | $117 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 42 | $2,962 | $52 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 41 | $2,696 | $55 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 14 | $1,627 | $90 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 13 | $1,590 | $114 |
| Injection of substance into lower spine canal using imaging guidance | 15 | $1,404 | $70 |
| Injection of substance into middle or upper spine canal using imaging guidance | 11 | $1,003 | $84 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 14 | $981 | $54 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 13 | $892 | $64 |
2022: 11 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 70 | $10,745 | $125 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 57 | $9,915 | $129 |
| New patient visit (45+ min) | 68 | $8,681 | $128 |
| Return visit (30+ min) | 53 | $6,228 | $102 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 51 | $3,397 | $57 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 36 | $2,526 | $55 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 17 | $2,387 | $114 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 17 | $1,346 | $64 |
| Injection of substance into lower spine canal using imaging guidance | 13 | $1,289 | $76 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,048 | $81 |
| Injection of substance into middle or upper spine canal using imaging guidance | 12 | $1,025 | $85 |
2021: 12 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 58 | $10,263 | $127 |
| Return visit (30+ min) | 58 | $9,255 | $110 |
| New patient visit (45+ min) | 62 | $8,586 | $138 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 49 | $4,337 | $87 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 14 | $3,647 | $192 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 17 | $3,071 | $118 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 31 | $2,503 | $54 |
| Injection of substance into lower spine canal using imaging guidance | 19 | $2,193 | $78 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 16 | $2,131 | $101 |
| Short return visit (20+ min) | 17 | $1,917 | $68 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 13 | $1,250 | $54 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 14 | $1,130 | $59 |
2020: 11 services
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 54 | $8,072 | $119 |
| Return visit (30+ min) | 42 | $5,642 | $99 |
| New patient visit (45+ min) | 45 | $5,628 | $125 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 32 | $2,834 | $89 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 20 | $2,592 | $104 |
| Injection of substance into lower spine canal using imaging guidance | 23 | $2,511 | $81 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 14 | $2,420 | $115 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 29 | $1,702 | $47 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 20 | $1,557 | $62 |
| Short return visit (20+ min) | 11 | $1,038 | $58 |
| Long return visit (40+ min) | 14 | $846 | $60 |
2019: 15 services
| Long return visit (40+ min) | 70 | $11,977 | $113 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 62 | $7,949 | $117 |
| New patient visit (45+ min) | 39 | $4,874 | $125 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 52 | $4,690 | $85 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 16 | $4,317 | $188 |
| Injection of substance into lower spine canal using imaging guidance | 27 | $3,174 | $79 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 22 | $2,435 | $101 |
| Injection of substance into middle or upper spine canal using imaging guidance | 17 | $1,706 | $81 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 34 | $1,706 | $46 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 12 | $1,501 | $125 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 20 | $1,300 | $59 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 16 | $1,236 | $52 |
| New patient visit (30+ min) | 14 | $1,230 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $927 | $62 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 15 | $352 | $15 |
2018: 14 services
| Long return visit (40+ min) | 75 | $13,488 | $111 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 58 | $7,109 | $95 |
| Injection of substance into lower spine canal using imaging guidance | 47 | $5,355 | $79 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 64 | $5,287 | $81 |
| New patient visit (45+ min) | 38 | $4,905 | $129 |
| Return visit (30+ min) | 43 | $4,094 | $82 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 16 | $3,938 | $188 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 30 | $3,278 | $84 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 27 | $1,731 | $49 |
| New patient visit (30+ min) | 18 | $1,557 | $87 |
| Injection of substance into middle or upper spine canal using imaging guidance | 16 | $1,461 | $86 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 28 | $1,430 | $39 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 11 | $1,118 | $93 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 15 | $985 | $52 |
2017: 17 services
| Long return visit (40+ min) | 119 | $20,855 | $102 |
| New patient visit (45+ min) | 52 | $6,698 | $129 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 56 | $6,601 | $106 |
| Injection of substance into lower spine canal using imaging guidance | 55 | $5,689 | $84 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 20 | $5,424 | $201 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 55 | $5,013 | $84 |
| Return visit (30+ min) | 40 | $3,492 | $85 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 30 | $3,052 | $85 |
| New patient visit (30+ min) | 25 | $2,301 | $92 |
| Injection of substance into middle or upper spine canal using imaging guidance | 17 | $1,882 | $94 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 27 | $1,630 | $49 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 13 | $1,500 | $94 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 17 | $1,239 | $54 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 24 | $1,124 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $966 | $57 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 13 | $914 | $57 |
| Injection of substance into lower spine canal using imaging guidance | 11 | $913 | $83 |
2016: 17 services
| Long return visit (40+ min) | 129 | $30,139 | $110 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 63 | $7,720 | $99 |
| Injections of substances into lower or sacral spine | 87 | $7,689 | $70 |
| New patient visit (45+ min) | 59 | $7,392 | $125 |
| Return visit (30+ min) | 68 | $6,652 | $71 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 68 | $6,146 | $83 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 23 | $5,473 | $203 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 23 | $2,139 | $89 |
| Injections of substances into upper or middle spine | 20 | $2,104 | $91 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 17 | $1,385 | $77 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 24 | $1,308 | $44 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 20 | $1,068 | $51 |
| Short return visit (20+ min) | 16 | $918 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $884 | $59 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 13 | $679 | $52 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $451 | $32 |
| Aspiration and/or injection of fluid from large joint | 11 | $386 | $35 |
2015: 10 services
| Long return visit (40+ min) | 65 | $10,367 | $118 |
| Return visit (30+ min) | 83 | $9,206 | $80 |
| Injections of substances into lower or sacral spine | 36 | $2,937 | $77 |
| New patient visit (45+ min) | 19 | $2,532 | $133 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 27 | $2,390 | $85 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 14 | $1,500 | $88 |
| Short return visit (20+ min) | 25 | $1,426 | $55 |
| Injections of substances into upper or middle spine | 14 | $1,405 | $94 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 14 | $848 | $50 |
| Injection of lower or sacral spine facet joint using imaging guidance, third and any additional level | 12 | $679 | $52 |
Medicaid work
$248,128 in 2024
Medicaid paid $248,128 for 1,133 billed services this clinician did in 2024, up to 46 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 339 | $79,718 |
| New patient visit (45+ min) | 226 | $52,237 |
| NJX INTERLAMINAR CRV/THRC | 90 | $33,507 |
| Return visit (30+ min) | 209 | $32,229 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level | 51 | $16,820 |
| NJX INTERLAMINAR LMBR/SAC | 42 | $15,775 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 142 | $11,752 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure) | 34 | $6,089 |
| 2024 | 1,133 | 8 | 46 | $248,128 |
| 2023 | 1,379 | 7 | 42 | $281,423 |
| 2022 | 1,114 | 7 | 42 | $226,549 |
| 2021 | 779 | 7 | 36 | $154,799 |
| 2020 | 561 | 6 | 34 | $99,272 |
| 2019 | 632 | 6 | 48 | $96,357 |
| 2018 | 763 | 9 | 34 | $155,159 |
See the largest Medicaid services in earlier years
2023
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 421 | $100,771 |
| New patient visit (45+ min) | 268 | $65,362 |
| Return visit (30+ min) | 299 | $49,117 |
| NJX INTERLAMINAR CRV/THRC | 57 | $26,379 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 226 | $19,909 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level | 45 | $13,051 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure) | 63 | $6,833 |
2022
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 353 | $73,345 |
| New patient visit (45+ min) | 277 | $67,505 |
| Return visit (30+ min) | 186 | $30,240 |
| NJX INTERLAMINAR CRV/THRC | 51 | $22,835 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level | 42 | $14,985 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 173 | $12,973 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure) | 32 | $4,666 |
2021
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 271 | $60,897 |
| New patient visit (45+ min) | 159 | $39,465 |
| Return visit (30+ min) | 253 | $38,238 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level | 14 | $6,820 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 49 | $4,609 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure) | 20 | $3,613 |
| 1ST HOSP IP/OBS SF/LOW 40 | 13 | $1,157 |
2020
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 211 | $43,289 |
| New patient visit (45+ min) | 100 | $24,540 |
| Return visit (30+ min) | 158 | $24,091 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 48 | $3,453 |
| 1ST HOSP IP/OBS SF/LOW 40 | 26 | $3,125 |
| Long return visit (40+ min) | 18 | $774 |
2019
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 182 | $36,212 |
| Long return visit (40+ min) | 257 | $25,411 |
| New patient visit (45+ min) | 78 | $17,392 |
| NJX INTERLAMINAR LMBR/SAC | 25 | $7,132 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 56 | $5,245 |
| 1ST HOSP IP/OBS SF/LOW 40 | 34 | $4,964 |
2018
| Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level | 244 | $53,829 |
| Long return visit (40+ min) | 222 | $46,016 |
| NJX INTERLAMINAR LMBR/SAC | 56 | $15,942 |
| 1ST HOSP IP/OBS SF/LOW 40 | 77 | $10,954 |
| Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint | 12 | $7,881 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level | 26 | $6,413 |
| Return visit (30+ min) | 41 | $6,378 |
| NJX AA&/STRD TFRML EPI LUMBAR/SACRAL EA ADDL | 72 | $6,357 |
| Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure) | 13 | $1,389 |
Drugs they prescribed that Part D paid
$52,683
Pharmacies billed $52,683 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 53% of their Part D prescriptions (604 of 1,151) in 2024. Above the middle of the specialty; the typical anesthesiology clinician is at 0%. Long-acting opioids: 17% of their opioid prescriptions.
1,077 generic and 74 brand-name prescriptions · $52,683 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Diclofenac Epolamine | 11 | $6,418 | $583 |
| Xtampza Er | 14 | $6,091 | $435 |
| Oxycodone-Acetaminophen | 196 | $4,709 | $24 |
| Oxycodone | 168 | $3,158 | $19 |
| Gabapentin | 135 | $2,179 | $16 |
See all 17 drugs
| Diclofenac Epolamine | 11 | $6,418 | $583 |
| Xtampza Er | 14 | $6,091 | $435 |
| Oxycodone-Acetaminophen | 196 | $4,709 | $24 |
| Oxycodone | 168 | $3,158 | $19 |
| Gabapentin | 135 | $2,179 | $16 |
| Naloxone | 33 | $2,007 | $61 |
| Morphine Sulfate Er | 55 | $1,953 | $36 |
| Lidocaine | 17 | $1,278 | $75 |
| Cyclobenzaprine | 88 | $1,057 | $12 |
| Tizanidine | 61 | $963 | $16 |
| Tramadol | 75 | $799 | $11 |
| Pregabalin | 50 | $797 | $16 |
| Hydrocodone-Acetaminophen | 37 | $652 | $18 |
| Celecoxib | 14 | $196 | $14 |
| Diclofenac | 12 | $140 | $12 |
| Acetaminophen-Codeine | 11 | $122 | $11 |
| Methylprednisolone | 19 | $112 | $6 |
Year by year
| 2024 | 1,151 | 329 | 53% (604) | 6% | $52,683 |
| 2023 | 1,095 | 260 | 53% (584) | 6% | $66,980 |
| 2022 | 980 | 210 | 47% (461) | 4% | $51,632 |
| 2021 | 1,047 | 180 | 47% (494) | 7% | $56,035 |
| 2020 | 987 | 169 | 52% (512) | 6% | $61,844 |
| 2019 | 1,071 | 189 | 63% (674) | 10% | $80,360 |
| 2018 | 1,150 | 185 | 59% (674) | 10% | $99,079 |
| 2017 | 1,151 | 186 | 60% (691) | 13% | $146,880 |
| 2016 | 1,070 | 144 | 63% (677) | None | $143,962 |
| 2015 | 481 | 167 | 54% (258) | 22% | $58,969 |
| 2014 | 27 | None | None | None | $3,063 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Oxycontin | 19 | $18,317 | $964 |
| Oxycodone-Acetaminophen | 172 | $4,674 | $27 |
| Xtampza Er | 11 | $4,463 | $406 |
| Oxycodone | 170 | $4,316 | $25 |
| Naloxone | 52 | $4,277 | $82 |
| Gabapentin | 113 | $2,306 | $20 |
| Morphine Sulfate Er | 43 | $2,146 | $50 |
| Tizanidine | 86 | $1,580 | $18 |
| Pregabalin | 30 | $1,268 | $42 |
| Hydrocodone-Acetaminophen | 45 | $1,046 | $23 |
| Tramadol | 71 | $963 | $14 |
| Cyclobenzaprine | 65 | $802 | $12 |
| Naproxen | 15 | $619 | $41 |
| Ibuprofen | 13 | $192 | $15 |
| Methylprednisolone | 15 | $160 | $11 |
| Acetaminophen-Codeine | 15 | $134 | $9 |
| Zolpidem | 11 | $102 | $9 |
| Hydromorphone | 13 | $100 | $8 |
2022: 17 drugs
| Oxycontin | 14 | $8,436 | $603 |
| Oxycodone-Acetaminophen | 134 | $4,115 | $31 |
| Gabapentin | 165 | $4,039 | $24 |
| Fentanyl | 13 | $4,002 | $308 |
| Oxycodone | 131 | $3,623 | $28 |
| Pregabalin | 47 | $2,484 | $53 |
| Naloxone | 22 | $2,026 | $92 |
| Cyclobenzaprine | 59 | $1,591 | $27 |
| Tizanidine | 67 | $1,488 | $22 |
| Morphine Sulfate Er | 32 | $1,451 | $45 |
| Hydrocodone-Acetaminophen | 28 | $840 | $30 |
| Hydromorphone | 34 | $670 | $20 |
| Tramadol | 53 | $299 | $6 |
| Baclofen | 14 | $290 | $21 |
| Naproxen | 13 | $90 | $7 |
| Zolpidem | 16 | $87 | $5 |
| Meloxicam | 31 | $61 | $2 |
2021: 19 drugs
| Fentanyl | 33 | $7,999 | $242 |
| Oxycodone | 120 | $6,272 | $52 |
| Oxycontin | 12 | $6,075 | $506 |
| Narcan | 43 | $5,666 | $132 |
| Oxycodone-Acetaminophen | 140 | $4,483 | $32 |
| Gabapentin | 170 | $3,810 | $22 |
| Morphine Sulfate Er | 38 | $3,495 | $92 |
| Pregabalin | 41 | $2,739 | $67 |
| Tizanidine | 72 | $1,851 | $26 |
| Cyclobenzaprine | 71 | $1,653 | $23 |
| Hydrocodone-Acetaminophen | 38 | $1,463 | $39 |
| Morphine Sulfate | 17 | $714 | $42 |
| Hydromorphone | 32 | $437 | $14 |
| Methylprednisolone | 26 | $355 | $14 |
| Butalbital-Acetaminophen-Caffe | 13 | $298 | $23 |
| Tramadol | 43 | $262 | $6 |
| Topiramate | 16 | $234 | $15 |
| Meloxicam | 27 | $139 | $5 |
| Zolpidem | 13 | $76 | $6 |
2020: 19 drugs
| Oxycontin | 23 | $15,689 | $682 |
| Fentanyl | 46 | $9,495 | $206 |
| Xtampza Er | 17 | $7,083 | $417 |
| Oxycodone-Acetaminophen | 122 | $4,650 | $38 |
| Oxycodone | 112 | $4,547 | $41 |
| Gabapentin | 158 | $3,360 | $21 |
| Morphine Sulfate Er | 78 | $3,090 | $40 |
| Tizanidine | 84 | $1,530 | $18 |
| Pregabalin | 17 | $1,189 | $70 |
| Cyclobenzaprine | 55 | $1,036 | $19 |
| Morphine Sulfate | 18 | $859 | $48 |
| Baclofen | 17 | $709 | $42 |
| Diclofenac | 13 | $570 | $44 |
| Methylprednisolone | 28 | $474 | $17 |
| Hydrocodone-Acetaminophen | 17 | $332 | $20 |
| Hydromorphone | 20 | $290 | $15 |
| Tramadol | 45 | $261 | $6 |
| Ibuprofen | 14 | $137 | $10 |
| Nortriptyline | 12 | $63 | $5 |
2019: 18 drugs
| Oxycontin | 38 | $24,922 | $656 |
| Fentanyl | 63 | $12,789 | $203 |
| Lyrica | 14 | $7,829 | $559 |
| Oxycodone-Acetaminophen | 140 | $6,920 | $49 |
| Oxycodone | 164 | $6,651 | $41 |
| Morphine Sulfate Er | 80 | $3,020 | $38 |
| Gabapentin | 122 | $2,973 | $24 |
| Hydrocodone-Acetaminophen | 49 | $1,745 | $36 |
| Morphine Sulfate | 24 | $1,684 | $70 |
| Tizanidine | 67 | $1,335 | $20 |
| Cyclobenzaprine | 42 | $899 | $21 |
| Methadone | 21 | $769 | $37 |
| Tramadol | 51 | $682 | $13 |
| Baclofen | 23 | $451 | $20 |
| Methylprednisolone | 26 | $383 | $15 |
| Hydromorphone | 16 | $372 | $23 |
| Acetaminophen-Codeine | 14 | $210 | $15 |
| Nortriptyline | 11 | $92 | $8 |
2018: 21 drugs
| Oxycontin | 49 | $42,593 | $869 |
| Lyrica | 15 | $13,791 | $919 |
| Oxycodone-Acetaminophen | 154 | $7,607 | $49 |
| Fentanyl | 51 | $6,042 | $118 |
| Oxycodone | 168 | $5,760 | $34 |
| Morphine Sulfate Er | 73 | $4,623 | $63 |
| Gabapentin | 166 | $3,095 | $19 |
| Endocet | 26 | $1,948 | $75 |
| Hydrocodone-Acetaminophen | 41 | $1,835 | $45 |
| Cyclobenzaprine | 39 | $1,372 | $35 |
| Morphine Sulfate | 19 | $1,053 | $55 |
| Tizanidine | 51 | $658 | $13 |
| Methadone | 30 | $646 | $22 |
| Tramadol | 36 | $349 | $10 |
| Baclofen | 15 | $280 | $19 |
| Duloxetine | 12 | $270 | $22 |
| Amitriptyline | 14 | $210 | $15 |
| Meloxicam | 46 | $192 | $4 |
| Lactulose | 18 | $191 | $11 |
| Methylprednisolone | 21 | $183 | $9 |
| Nortriptyline | 25 | $159 | $6 |
2017: 20 drugs
| Oxycontin | 66 | $69,879 | $1,059 |
| Lyrica | 25 | $14,215 | $569 |
| Fentanyl | 74 | $11,208 | $151 |
| Oxycodone-Acetaminophen | 123 | $6,530 | $53 |
| Oxycodone | 177 | $6,167 | $35 |
| Morphine Sulfate Er | 53 | $4,633 | $87 |
| Endocet | 44 | $3,588 | $82 |
| Gabapentin | 139 | $2,669 | $19 |
| Hydrocodone-Acetaminophen | 52 | $1,340 | $26 |
| Cyclobenzaprine | 32 | $1,172 | $37 |
| Tizanidine | 50 | $1,088 | $22 |
| Morphine Sulfate | 19 | $970 | $51 |
| Amitriptyline | 27 | $740 | $27 |
| Methadone | 23 | $462 | $20 |
| Baclofen | 25 | $435 | $17 |
| Tramadol | 32 | $394 | $12 |
| Nortriptyline | 35 | $310 | $9 |
| Duloxetine | 14 | $296 | $21 |
| Lactulose | 17 | $199 | $12 |
| Meloxicam | 25 | $137 | $5 |
2016: 22 drugs
| Oxycontin | 74 | $57,390 | $776 |
| Lyrica | 47 | $23,344 | $497 |
| Oxycodone-Acetaminophen | 167 | $9,859 | $59 |
| Fentanyl | 66 | $9,652 | $146 |
| Oxycodone | 149 | $6,648 | $45 |
| Endocet | 60 | $5,758 | $96 |
| Morphine Sulfate Er | 54 | $5,067 | $94 |
| Lidocaine | 15 | $4,033 | $269 |
| Hydrocodone-Acetaminophen | 49 | $1,893 | $39 |
| Desipramine | 11 | $1,440 | $131 |
| Gabapentin | 91 | $1,113 | $12 |
| Tizanidine | 41 | $1,053 | $26 |
| Hydromorphone | 13 | $859 | $66 |
| Amitriptyline | 39 | $734 | $19 |
| Morphine Sulfate | 13 | $594 | $46 |
| Methadone | 22 | $425 | $19 |
| Duloxetine | 20 | $332 | $17 |
| Cyclobenzaprine | 13 | $250 | $19 |
| Nortriptyline | 24 | $127 | $5 |
| Lactulose | 12 | $97 | $8 |
| Meloxicam | 13 | $81 | $6 |
| Prednisone | 14 | $32 | $2 |
2015: 17 drugs
| Oxycontin | 41 | $24,223 | $591 |
| Lyrica | 13 | $7,602 | $585 |
| Lidocaine | 26 | $4,345 | $167 |
| Fentanyl | 23 | $3,331 | $145 |
| Oxycodone-Acetaminophen | 50 | $2,747 | $55 |
| Endocet | 25 | $2,597 | $104 |
| Oxycodone | 52 | $1,980 | $38 |
| Voltaren | 13 | $1,148 | $88 |
| Morphine Sulfate Er | 11 | $1,125 | $102 |
| Gabapentin | 46 | $1,017 | $22 |
| Tizanidine | 35 | $698 | $20 |
| Hydrocodone-Acetaminophen | 13 | $533 | $41 |
| Methadone | 12 | $284 | $24 |
| Cyclobenzaprine | 11 | $245 | $22 |
| Meloxicam | 14 | $114 | $8 |
| Nortriptyline | 12 | $79 | $7 |
| Tramadol | 14 | $70 | $5 |
Money from drug and device companies
$682 in 2025
| 2025 | 5 | 10 | None | $682 |
| 2024 | 4 | 5 | None | $472 |
| 2023 | 8 | 14 | None | $619 |
| 2022 | 6 | 17 | None | $734 |
| 2021 | 8 | 27 | None | $1,074 |
| 2020 | 3 | 3 | None | $244 |
| 2019 | 8 | 13 | None | $532 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Wavewriter Alpha Prime 16 | $243 | 5 payments
|
| Medtronic | Intellis Adaptivestim | $227 | 1 payment
|
| Abbott Laboratories | Eterna | $72 | 1 payment
|
| Saluda Medical Americas | Evoke | $72 | 1 payment
|
| Globus Medical | Senza | $67 | 2 payments
|
See all 10 published payments
| Boston Scientific | Meals · 2025-11-19 | General - Kidney Stone Disease | $37 |
| Globus Medical | Meals · 2025-11-19 | Senza | $33 |
| Globus Medical | Meals · 2025-11-12 | Senza | $35 |
| Boston Scientific | Meals · 2025-11-11 | Intracept | $19 |
| Boston Scientific | Meals · 2025-11-03 | General - Pain Management | $12 |
| Saluda Medical Americas | Meals · 2025-10-09 | Evoke | $72 |
| Boston Scientific | Meals · 2025-08-06 | General - Pain Management | $25 |
| Abbott Laboratories | Meals · 2025-06-23 | Eterna | $72 |
| Boston Scientific | Meals · 2025-03-20 | Wavewriter Alpha Prime 16 | $149 |
| Medtronic | Meals · 2025-03-12 | Intellis Adaptivestim | $227 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $472
| Boston Scientific | Wavewriter Alpha Prime 16 | $162 | 2 payments
|
| Vertos Medical | Mild Device Kit | $134 | 1 payment
|
| Saluda Medical Americas | Evoke | $103 | 1 payment
|
| Abbott Laboratories | Proclaim | $73 | 1 payment
|
2023: $619
| Boston Scientific | None | $246 | 5 payments
|
| Medtronic | Intellis Adaptivestim | $141 | 1 payment
|
| Pacira Pharmaceuticals | Exparel | $101 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $60 | 3 payments
|
| Nevro | Senza | $21 | 1 payment
|
| Saluda Medical Americas | Evoke Scs | $19 | 1 payment
|
| Abbvie | Botox | $16 | 1 payment
|
| Collegium Pharmaceutical | Belbuca | $15 | 1 payment
|
2022: $734
| Boston Scientific | General - Pain Management | $356 | 6 payments
|
| Nevro | Omnia | $207 | 4 payments
|
| Abbott Laboratories | Axium | $65 | 1 payment
|
| Medtronic | Intellis Adaptivestim | $48 | 2 payments
|
| Collegium Pharmaceutical | Xtampza | $31 | 2 payments
|
| Abbvie | Botox | $27 | 2 payments
|
2021: $1,074
| Boston Scientific | General Pain Management | $288 | 5 payments
|
| Abbott Laboratories | Proclaim Ipg | $254 | 4 payments
|
| Medtronic | Intellis | $201 | 5 payments
|
| Si-Bone | Ifuse Implant | $114 | 2 payments
|
| Nevro | Omnia | $102 | 3 payments
|
| Collegium Pharmaceutical | Xtampza | $87 | 6 payments
|
| GRT US Holding | Qutenza | $15 | 1 payment
|
| BioDelivery Sciences International | Belbuca | $13 | 1 payment
|
2020: $244
| Medtronic USA | Restore | $120 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $109 | 1 payment
|
| Collegium Pharmaceutical | Xtampza | $15 | 1 payment
|
2019: $532
| Abbott Laboratories | Proclaim Family of Scs Ipgs | $214 | 2 payments
|
| Vertiflex | Superion Iss | $134 | 1 payment
|
| Stimwave Technologies | None | $45 | 1 payment
|
| Collegium Pharmaceutical | Xtampza | $41 | 3 payments
|
| BioDelivery Sciences International | Bunavail 2.1 Mg 30-Count Box | $28 | 2 payments
|
| Nevro | Senza Spinal Cord Stimulation System | $26 | 2 payments
|
| Boston Scientific | General Pain Management | $24 | 1 payment
|
| Medtronic USA | Intellis | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1336584762
- Licence
- CA A118273, NJ 25MA09636600California A118273: Current · expires 2027-09-30New Jersey 25MA09636600: Active
- Trained
- Rutgers New Jersey Medical School, 2010
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 1 Federal St Ste Sw200, Camden, NJ, 08103
- NPI first listed
- 2013-04-29
- NPI last updated
- 2018-03-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305